Author

Christopher Divsalar

Fresenius Kabi (United States)ORCID 0009-0001-9019-2602Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Alessandro SinopoliiD· 1 shared Alvin HsuiD· 1 shared Amélie WiederkehriD· 1 shared André LieberiD· 1 shared Anna CamusiD· 1 shared Chang Long LiiD· 1 shared David R. LiuiD· 1 shared Diego CalabreseiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Alessandro SinopoliORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates β-thalassemia model

Romina Marone, Rosalba Lepore, Kiriaki Paschoudi, Jessica Zuin, Alessandro Sinopoli, Anna Camus, Thomas Burgold, Ewelina Magdalena Bartoszek, Diego Calabrese, Mylene Toranelli, Julia Rositzka, Manuel Rhiel, Geoffroy Andrieux, Chang Long Li, Alvin Hsu, , Lukas T. Jeker

This paper demonstrates a method using CD117-blocking antibody and epitope-engineered HSPCs to treat β-thalassemia without myeloablative conditioning.

bioRxiv · Jul 8, 2026 · PreprintBioengineering